HRP20080495T3 - 8-hydroxy-5- [(-hydroxy-2- [[ (1r)-2-(4-methoxyphenyl)-1-methylethyl] amino ][ethyl -2(1h)-quinolinone monohydrochloride in crystalline form and the process for its preparation - Google Patents
8-hydroxy-5- [(-hydroxy-2- [[ (1r)-2-(4-methoxyphenyl)-1-methylethyl] amino ][ethyl -2(1h)-quinolinone monohydrochloride in crystalline form and the process for its preparationInfo
- Publication number
- HRP20080495T3 HRP20080495T3 HR20080495T HRP20080495T HRP20080495T3 HR P20080495 T3 HRP20080495 T3 HR P20080495T3 HR 20080495 T HR20080495 T HR 20080495T HR P20080495 T HRP20080495 T HR P20080495T HR P20080495 T3 HRP20080495 T3 HR P20080495T3
- Authority
- HR
- Croatia
- Prior art keywords
- hydroxy
- methylethyl
- methoxyphenyl
- ethyl
- amino
- Prior art date
Links
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 title 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 title 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 title 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 abstract 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
- C07D215/60—N-oxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04007045 | 2004-03-24 | ||
| PCT/EP2005/003144 WO2005089760A1 (en) | 2004-03-24 | 2005-03-24 | 8-hydroxy-5-[(-hydroxy-2-[[ (1r)-2-(4-methoxyphenyl)-1-methylethyl] amino ][ethyl] -2(1h)-quinolinone monohydrochloride in crystalline form and the process for its preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20080495T3 true HRP20080495T3 (en) | 2008-11-30 |
Family
ID=34963779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20080495T HRP20080495T3 (en) | 2004-03-24 | 2008-10-01 | 8-hydroxy-5- [(-hydroxy-2- [[ (1r)-2-(4-methoxyphenyl)-1-methylethyl] amino ][ethyl -2(1h)-quinolinone monohydrochloride in crystalline form and the process for its preparation |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US20070197586A1 (sr) |
| EP (1) | EP1729773B1 (sr) |
| JP (1) | JP2007530489A (sr) |
| KR (1) | KR20070001946A (sr) |
| CN (2) | CN1929840B (sr) |
| AR (1) | AR048339A1 (sr) |
| AT (1) | ATE399552T1 (sr) |
| AU (1) | AU2005224032A1 (sr) |
| BR (1) | BRPI0508213A (sr) |
| CA (1) | CA2560650A1 (sr) |
| CY (1) | CY1108323T1 (sr) |
| DE (1) | DE602005007871D1 (sr) |
| DK (1) | DK1729773T3 (sr) |
| EA (1) | EA010128B1 (sr) |
| ES (1) | ES2309739T3 (sr) |
| HR (1) | HRP20080495T3 (sr) |
| IL (1) | IL178227A0 (sr) |
| MA (1) | MA28549B1 (sr) |
| MX (1) | MXPA06010515A (sr) |
| NO (1) | NO20064274L (sr) |
| NZ (1) | NZ550010A (sr) |
| PE (1) | PE20060159A1 (sr) |
| PL (1) | PL1729773T3 (sr) |
| PT (1) | PT1729773E (sr) |
| RS (1) | RS50602B (sr) |
| SI (1) | SI1729773T1 (sr) |
| TN (1) | TNSN06249A1 (sr) |
| UA (1) | UA86221C2 (sr) |
| WO (1) | WO2005089760A1 (sr) |
| ZA (1) | ZA200607907B (sr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1953143A1 (en) * | 2007-01-30 | 2008-08-06 | CHIESI FARMACEUTICI S.p.A. | Process for the preparation of 8-hydroxy-5-[(1R)-1-hydroxy-2[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride |
| EP2116536A1 (en) * | 2008-05-07 | 2009-11-11 | CHIESI FARMACEUTICI S.p.A. | Crystal form of 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1h)- quinolinone monohydrochloride |
| EP2116537A1 (en) | 2008-05-07 | 2009-11-11 | CHIESI FARMACEUTICI S.p.A. | Polymorph of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride |
| WO2011015289A1 (en) | 2009-08-04 | 2011-02-10 | Chiesi Farmaceutici S.P.A. | 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl] amino]ethyl]-2(1h)-quinolinone hemi-fumarate |
| EP2360147A1 (en) | 2010-02-22 | 2011-08-24 | CHIESI FARMACEUTICI S.p.A. | Process for preparing crystalline particles of a salt of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino] ethyl]-2(1H)-quinolinone (carmoterol) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8334494D0 (en) * | 1983-12-24 | 1984-02-01 | Tanabe Seiyaku Co | Carbostyril derivatives |
| GB9603237D0 (en) * | 1996-02-16 | 1996-04-17 | Sandoz Ltd | Organic compounds |
| SE9700135D0 (sv) * | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
| JP2007501194A (ja) * | 2003-08-05 | 2007-01-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ステロイドとβ模倣薬を含む吸入用薬剤 |
| EP1953143A1 (en) * | 2007-01-30 | 2008-08-06 | CHIESI FARMACEUTICI S.p.A. | Process for the preparation of 8-hydroxy-5-[(1R)-1-hydroxy-2[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride |
| EP2116536A1 (en) * | 2008-05-07 | 2009-11-11 | CHIESI FARMACEUTICI S.p.A. | Crystal form of 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1h)- quinolinone monohydrochloride |
| EP2116537A1 (en) * | 2008-05-07 | 2009-11-11 | CHIESI FARMACEUTICI S.p.A. | Polymorph of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride |
-
2005
- 2005-03-23 AR ARP050101185A patent/AR048339A1/es not_active Application Discontinuation
- 2005-03-23 PE PE2005000338A patent/PE20060159A1/es not_active Application Discontinuation
- 2005-03-24 BR BRPI0508213-7A patent/BRPI0508213A/pt not_active IP Right Cessation
- 2005-03-24 DE DE602005007871T patent/DE602005007871D1/de active Active
- 2005-03-24 UA UAA200609448A patent/UA86221C2/uk unknown
- 2005-03-24 CA CA002560650A patent/CA2560650A1/en not_active Abandoned
- 2005-03-24 MX MXPA06010515A patent/MXPA06010515A/es active IP Right Grant
- 2005-03-24 ES ES05730069T patent/ES2309739T3/es active Active
- 2005-03-24 CN CN2005800076387A patent/CN1929840B/zh not_active Expired - Fee Related
- 2005-03-24 WO PCT/EP2005/003144 patent/WO2005089760A1/en active Application Filing
- 2005-03-24 KR KR1020067015966A patent/KR20070001946A/ko not_active Application Discontinuation
- 2005-03-24 EP EP05730069A patent/EP1729773B1/en active Active
- 2005-03-24 AT AT05730069T patent/ATE399552T1/de not_active IP Right Cessation
- 2005-03-24 RS RSP-2008/0393A patent/RS50602B/sr unknown
- 2005-03-24 JP JP2007504359A patent/JP2007530489A/ja not_active Withdrawn
- 2005-03-24 EA EA200601531A patent/EA010128B1/ru not_active IP Right Cessation
- 2005-03-24 AU AU2005224032A patent/AU2005224032A1/en not_active Abandoned
- 2005-03-24 NZ NZ550010A patent/NZ550010A/en unknown
- 2005-03-24 US US10/593,571 patent/US20070197586A1/en not_active Abandoned
- 2005-03-24 SI SI200530320T patent/SI1729773T1/sl unknown
- 2005-03-24 PT PT05730069T patent/PT1729773E/pt unknown
- 2005-03-24 CN CN200910173473A patent/CN101812017A/zh active Pending
- 2005-03-24 PL PL05730069T patent/PL1729773T3/pl unknown
- 2005-03-24 DK DK05730069T patent/DK1729773T3/da active
-
2006
- 2006-08-04 TN TNP2006000249A patent/TNSN06249A1/en unknown
- 2006-09-21 NO NO20064274A patent/NO20064274L/no not_active Application Discontinuation
- 2006-09-21 IL IL178227A patent/IL178227A0/en not_active IP Right Cessation
- 2006-09-21 ZA ZA2006/07907A patent/ZA200607907B/en unknown
- 2006-10-23 MA MA29409A patent/MA28549B1/fr unknown
-
2008
- 2008-09-04 CY CY20081100962T patent/CY1108323T1/el unknown
- 2008-10-01 HR HR20080495T patent/HRP20080495T3/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE399552T1 (de) | 2008-07-15 |
| EA010128B1 (ru) | 2008-06-30 |
| CN1929840A (zh) | 2007-03-14 |
| TNSN06249A1 (en) | 2007-12-03 |
| JP2007530489A (ja) | 2007-11-01 |
| DK1729773T3 (da) | 2008-10-20 |
| CA2560650A1 (en) | 2005-09-29 |
| CN1929840B (zh) | 2010-12-08 |
| WO2005089760A1 (en) | 2005-09-29 |
| UA86221C2 (en) | 2009-04-10 |
| IL178227A0 (en) | 2006-12-31 |
| AR048339A1 (es) | 2006-04-19 |
| PL1729773T3 (pl) | 2008-12-31 |
| EP1729773A1 (en) | 2006-12-13 |
| MA28549B1 (fr) | 2007-04-03 |
| ZA200607907B (en) | 2008-04-30 |
| SI1729773T1 (sl) | 2008-10-31 |
| KR20070001946A (ko) | 2007-01-04 |
| BRPI0508213A (pt) | 2007-07-17 |
| RS50602B (sr) | 2010-05-07 |
| DE602005007871D1 (de) | 2008-08-14 |
| PT1729773E (pt) | 2008-09-29 |
| MXPA06010515A (es) | 2007-03-30 |
| AU2005224032A1 (en) | 2005-09-29 |
| EP1729773B1 (en) | 2008-07-02 |
| NZ550010A (en) | 2010-08-27 |
| PE20060159A1 (es) | 2006-04-04 |
| ES2309739T3 (es) | 2008-12-16 |
| CN101812017A (zh) | 2010-08-25 |
| US20070197586A1 (en) | 2007-08-23 |
| EA200601531A1 (ru) | 2007-04-27 |
| NO20064274L (no) | 2006-10-13 |
| CY1108323T1 (el) | 2014-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20080495T3 (en) | 8-hydroxy-5- [(-hydroxy-2- [[ (1r)-2-(4-methoxyphenyl)-1-methylethyl] amino ][ethyl -2(1h)-quinolinone monohydrochloride in crystalline form and the process for its preparation | |
| CA2936408C (en) | Triazine compounds and pharmaceutical use thereof | |
| US20200407319A1 (en) | Alkynyl pyridine prolyl hydroxylase inhibitor, and preparation method and medical use thereof | |
| MX2021010242A (es) | Compuesto inhibidor de jak y uso del mismo. | |
| TW201100393A (en) | Substituted aminobutyric derivatives as neprilysin inhibitors | |
| AR029857A1 (es) | Derivados de acidos sulfonil-amino-metil-benzoicos sustituidos y procedimiento para su preparacion | |
| WO2021111179A8 (en) | Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1s)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine | |
| EA201992501A1 (ru) | Соль соединения производного аминопиридина, ее кристаллическая форма и способ получения | |
| EA201100354A1 (ru) | Полиморф в n-(2-аминофенил)-4-[n-(пиридин-3-ил)-метоксикарбониламинометил]бензамида (ms-275) | |
| EA200400311A1 (ru) | Кристаллы производных гидроксинорэфедрина | |
| HRP20090236T1 (en) | Derivatives of pyrido[2,3-d]pyrimidine, the preparation thereof and the therapeutic application of the same | |
| WO2010128355A3 (en) | Improved processes for preparing substantially pure arformoterol and its intermediates | |
| WO2008035380A3 (en) | An improved process for the preparation of high purity formoterol and its pharmaceutically acceptable salts | |
| MX2021009796A (es) | Inhibidores selectivos de la proteina arginina metiltransferasa 5 (prmt5). | |
| FI105029B (fi) | Menetelmä terapeuttisesti käyttökelpoisten 4-amino-2-ureido-pyrimidiini-5-karboksyylihappoamidien valmistamiseksi, välituotteita ja niiden valmistus | |
| BR112014028362A2 (pt) | Ácidos (3r, 4r, 5s)-5-guanidino-4acetamido-3-(pentan- 3iloxi)cicloexeno-1-carboxílicos flúor substituídos, os seus ésteres e uso dos mesmos | |
| US11116736B2 (en) | 2-amino-N'-benzylideneacetohydrazides and derivatives for the management of CFTR protein mediated diseases | |
| US20200255422A1 (en) | Inhibitors of trim33 and methods of use | |
| SK30394A3 (en) | Derivatives of 2,4-diamino-3-hydroxycarboxylic acid, method of their preparation, pharmaceutical compositions containing these derivatives and their use | |
| WO2021055797A9 (en) | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) | |
| WO2021060947A3 (ko) | 유사 세라마이드의 신규한 합성방법 및 그에 관한 중간체 화합물 | |
| CA2789606A1 (en) | Peptide analogues as opioid receptor agonists | |
| WO2013162298A1 (ko) | 신규한 베타 알라닌 유도체, 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 약제학적 조성물 | |
| CA3154064A1 (en) | The salts of a compound and the crystalline forms thereof | |
| IL211747A (en) | Reliable aryl sulfonamide compounds and their use as 5–6ht ligands |